Clinical Trial Update: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating ublituximab for relapses in neuromyelitis optica and related spectrum disorders; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 1 | Status: COMPLETED | Results posted: 2019-06-06